These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 18645702)
41. Using statins to reduce cardiovascular risk after carotid endarterectomy. Floros G; Anagnostou V; Tsiga E; Ferenidou F; Papadimitriou D Evid Based Cardiovasc Med; 2006 Mar; 10(1):1-4. PubMed ID: 16530653 [No Abstract] [Full Text] [Related]
42. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders. Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821 [No Abstract] [Full Text] [Related]
43. Lipoprotein metabolism and lipid management in chronic kidney disease. Kwan BC; Kronenberg F; Beddhu S; Cheung AK J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943 [No Abstract] [Full Text] [Related]
44. Dyslipidaemia, statins and rheumatoid arthritis. Nurmohamed MT; Dijkmans BA Ann Rheum Dis; 2009 Apr; 68(4):453-5. PubMed ID: 19286903 [No Abstract] [Full Text] [Related]
45. Will obesity increase the proportion of children and adolescents recommended for a statin? McCrindle BW; Tyrrell PN; Kavey RE Circulation; 2013 Nov; 128(19):2162-5. PubMed ID: 24190936 [No Abstract] [Full Text] [Related]
47. Modulation of heat shock proteins by statins. Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271 [TBL] [Abstract][Full Text] [Related]
48. [Statins: what is their place in the treatment of chronic kidney insufficiency?]. Ponte B; Bourquin V; Stoermann-Chopard C Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313 [TBL] [Abstract][Full Text] [Related]
49. The use of lipid-lowering drug therapy in children and adolescents. Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879 [TBL] [Abstract][Full Text] [Related]
50. [Effect of statins on renal function]. Kasahara M Nihon Jinzo Gakkai Shi; 2013; 55(7):1295-300. PubMed ID: 24288966 [No Abstract] [Full Text] [Related]
51. Reinitiation of statins after statin-associated musculoskeletal symptoms: a patient-centered approach. Brito JP; Montori VM Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):243-7. PubMed ID: 23481527 [No Abstract] [Full Text] [Related]
52. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395 [TBL] [Abstract][Full Text] [Related]
53. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Robson J Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534 [No Abstract] [Full Text] [Related]
54. Starting statins for primary prevention of cardiovascular disease. Tunstall-Pedoe H Heart; 2013 Nov; 99(21):1547-8. PubMed ID: 23878178 [No Abstract] [Full Text] [Related]
55. The role of statins in the setting of HIV infection. Eckard AR; McComsey GA Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687 [TBL] [Abstract][Full Text] [Related]